Samuel S. Blumenthal, MD

Publications

• Hemoglobin Cast Nephropathy

  (Mahmud S, Dernell C, Bal N, Gallan AJ, Blumenthal S, Koratala A, Sturgill D.) Kidney International Reports. September 2020;5(9):1581-1585 SCOPUS ID: 2-s2.0-85089487078 09/01/2020

• Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.

  (Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, Jefferson JA, Gipson PE, Rizk DV, Sedor JR, Simon JF, McCarthy ET, Brenchley P, Sethi S, Avila-Casado C, Beanlands H, Lieske JC, Philibert D, Li T, Thomas LF, Green DF, Juncos LA, Beara-Lasic L, Blumenthal SS, Sussman AN, Erickson SB, Hladunewich M, Canetta PA, Hebert LA, Leung N, Radhakrishnan J, Reich HN, Parikh SV, Gipson DS, Lee DK, da Costa BR, Jüni P, Cattran DC, MENTOR Investigators.) N Engl J Med. 2019 Jul 04;381(1):36-46 PMID: 31269364 SCOPUS ID: 2-s2.0-85068552015 07/04/2019

• Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

  (Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D, SONAR Committees and Investigators.) Lancet. 2019 May 11;393(10184):1937-1947 PMID: 30995972 SCOPUS ID: 2-s2.0-85065234142 04/19/2019

• Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.

  (Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, DECLARE–TIMI 58 Investigators.) N Engl J Med. 2019 Jan 24;380(4):347-357 PMID: 30415602 SCOPUS ID: 2-s2.0-85060042753 11/13/2018

• Primary membranous nephropathy: comprehensive review and historical perspective.

  (Keri KC, Blumenthal S, Kulkarni V, Beck L, Chongkrairatanakul T.) Postgrad Med J. 2019 Jan;95(1119):23-31 PMID: 30683678 SCOPUS ID: 2-s2.0-85060638007 01/27/2019

• Effect of PF-04634817, an Oral CCR2/5 Chemokine Receptor Antagonist, on Albuminuria in Adults with Overt Diabetic Nephropathy

  (Gale JD, Gilbert S, Blumenthal S, Elliott T, Pergola PE, Goteti K, Scheele W, Perros-Huguet C.) Kidney International Reports. November 2018;3(6):1316-1327 SCOPUS ID: 2-s2.0-85053714369 11/01/2018

• Anti-TGF-β1 Antibody Therapy in Patients with Diabetic Nephropathy.

  (Voelker J, Berg PH, Sheetz M, Duffin K, Shen T, Moser B, Greene T, Blumenthal SS, Rychlik I, Yagil Y, Zaoui P, Lewis JB.) J Am Soc Nephrol. 2017 Mar;28(3):953-962 PMID: 27647855 PMCID: PMC5328150 SCOPUS ID: 2-s2.0-85021850104 09/21/2016

• Association of 3 Different Antihypertensive Medications With Hip and Pelvic Fracture Risk in Older Adults: Secondary Analysis of a Randomized Clinical Trial.

  (Puttnam R, Davis BR, Pressel SL, Whelton PK, Cushman WC, Louis GT, Margolis KL, Oparil S, Williamson J, Ghosh A, Einhorn PT, Barzilay JI, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Collaborative Research Group.) JAMA Intern Med. 2017 Jan 01;177(1):67-76 PMID: 27893045 SCOPUS ID: 2-s2.0-85011294803 11/29/2016

• Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD.

  (Umanath K, Jalal DI, Greco BA, Umeukeje EM, Reisin E, Manley J, Zeig S, Negoi DG, Hiremath AN, Blumenthal SS, Sika M, Niecestro R, Koury MJ, Ma KN, Greene T, Lewis JB, Dwyer JP, Collaborative Study Group.) J Am Soc Nephrol. 2015 Oct;26(10):2578-87 PMID: 25736045 PMCID: PMC4587699 SCOPUS ID: 2-s2.0-84941178726 03/05/2015

• Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

  (Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drüeke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J, Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators*.) Circulation. 2015 Jul 07;132(1):27-39 PMID: 26059012 SCOPUS ID: 2-s2.0-84935451711 06/11/2015

• The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.

  (Parfrey PS, Drüeke TB, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Moe SM, Wheeler DC, Kubo Y, Dehmel B, Goodman WG, Chertow GM, Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators.) Clin J Am Soc Nephrol. 2015 May 07;10(5):791-9 PMID: 25710802 PMCID: PMC4422239 SCOPUS ID: 2-s2.0-84929171843 02/25/2015

• A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR).

  (Fervenza FC, Canetta PA, Barbour SJ, Lafayette RA, Rovin BH, Aslam N, Hladunewich MA, Irazabal MV, Sethi S, Gipson DS, Reich HN, Brenchley P, Kretzler M, Radhakrishnan J, Hebert LA, Gipson PE, Thomas LF, McCarthy ET, Appel GB, Jefferson JA, Eirin A, Lieske JC, Hogan MC, Greene EL, Dillon JJ, Leung N, Sedor JR, Rizk DV, Blumenthal SS, Lasic LB, Juncos LA, Green DF, Simon J, Sussman AN, Philibert D, Cattran DC, Mentor Consortium group.) Nephron. 2015;130(3):159-68 PMID: 26087670 SCOPUS ID: 2-s2.0-84979809751 06/20/2015